


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/671,538
				Filing Date	September 29, 2003
				First Named Inventor	Bernard S.GREEN et al
				Art Unit	1618
				Examiner Name	ROGERS, JAMES WILLIAM
Sheet	1	of	3	Attorney Docket Number	26883

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ² Number ⁴ Kind Code ³ (if known)			
Examiner Signature				Date Considered	11/3/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/671,538		
(use as many sheets as necessary)			Filing Date	September 29, 2003		
			First Named Inventor	Bernard S.GREEN et al		
			Group Art Unit	1618		
			Examiner Name	ROGERS, JAMES WILLIAM		
Sheet	2	Of	3	Attorney Docket Number	26883	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²	
JA	11	Haupt et al. "Plastic Antibodies: Development and Applications", TIBTECH, 16: 468-475, 1998.				
	12	Mayes et al. "Molecularly Imprinted Polymers: Useful Materials for Analytical Chemistry?", Trends in Analytical Chemistry, 16(6): 321-332, 1997.				
	13	Vlatakis et al. "Drug Assay Using Antibody Mimics Made by Molecular Imprinting", Nature, 361: 645-647, 1993.				
	14	Kauer et al. "Composition and Concentration of Bile Acid Reflux Into the Esophagus of Patients With Gastroesophageal Reflux Disease", Surgery, 122: 874-881, 1997.				
	15	Ochsenkühn et al. "Colonic Mucosal Proliferation Is Related to Serum Deoxycholic Acid Levels", Cancer, 85: 1664-1669, 1999.				
	16	Shirvani et al. "Cyclooxygenase 2 Expression in Barrett's Esophagus and Adenocarcinoma: Ex Vivo Induction by Bile Salts and Acid Exposure", Gastroenterology, 118: 487-496, 2000.				
	17	Theisen et al. "Suppression of Gastric Acid Secretion in Patients With Gastroesophageal Reflux Disease Results in Gastric Bacterial Acids", Journal of Gastrointestinal Surgery, 4: 50-54, 2000.				
	18	Kamano et al. "Ratio of Primary and Secondary Bile Acids in Feces: Possible Marker for Colorectal Cancer?", Dis Colon Rectum, 42(5): 668-672, 1999. Abstract.				
	19	Nehra et al. "Toxic Bile Acids in Gastro-Oesophageal Reflux Disease: Influence of Gastric Acidity", GUT, 44(5): 598-602, 1999. Abstract.				
	20	Shindo et al. "Omeprazole Induces Altered Bile Acid Metabolism", GUT, 42: 266-271, 1998. Abstract.				
	21	Zhang et al. "Dihydroxy Bile Acids Activate the Transcription of Cyclooxygenase-2", The Journal of Biological Chemistry, 273(4): 2424-2428, 1998.				
	22	Whitcombe et al. "A New Method for the Introduction of Recognition Site Functionality Into Polymers Prepared by Molecular Imprinting: Synthesis and Characterization of Polymeric Receptors for Cholesterol", Journal of the American Chemical Society, 117: 7105-7111, 1995. Abstract.				
	23	Bayerdorffer et al. "Unconjugated Secondary Bile Acids in the Serum of Patients With Colorectal Adenomas", GUT, 36(2): 268-273, 1995. Abstract.				
	24	Berr et al. "Disorders of Bile Acid Metabolism in Cholesterol Gallstone Disease", Journal of Clinical Investigation, 90(3): 859-868, 1992.				
	25	Bernstein et al. "A Bile Acid-Induced Apoptosis Assay for Colon Cancer Risk and Associated Quality Control Studies", Cancer Research, 59(10): 2353-2357, 1999.				
	26	Fuhrman et al. "Increased Uptake of LDL by Oxidized Macrophages Is the Result of An Initial Enhanced LDL Receptor Activity and of A Further Progressive Oxidation of LDL", Free Radic Biol Med, 23(1): 34-46, 1997. Abstract.				
	Signature	JA			Considered	11/3/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/671,538		
		Filing Date	September 29, 2003		
		First Named Inventor	Bernard S.GREEN et al		
		Group Art Unit	1618		
		Examiner Name	ROGERS, JAMES WILLIAM		
Sheet	3	Of	3	Attorney Docket Number	26883
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
9A	27	Ljubuncic et al. "Effect of Deoxycholic Acid and Ursodeoxycholic Acid on Lipid Peroxidation in Cultured Macrophages", GUT, 39(3): 475-478, 1996. Abstract.			
	28	Low-Beer et al. "Colonic Bacterial Activity, Biliary Cholesterol Saturation, and Pathogenesis of Gallstones", Lancet, 2(8099): 1063-1065, 1978. Abstract.			
	29	Peiffer et al. "Differential Effects of Deoxycholic Acid on Proliferation of Neoplastic and Differentiation Colonocytes In Vitro", Digestive Diseases and Sciences, 42(11): 2234-2240, 1997. Abstract.			
	30	Shoda et al. "Increase of Deoxycholate in Supersaturated Bile of Patients With Cholesterol Gallstone Disease and Its Correlation With De Novo Syntheses of Cholesterol and Bile Acids in Liver, Gallbladder Emptying, and Small Intestinal Transit", Hepatology, 21(5): 1291-1302, 1995. Abstract.			
	31	Fini et al. "Spectrophotometric Determination of Bile Acids. An Evaluation", Collection of the Czechoslovakian Chemical Communications, 58(1): 53-61, 1993. Abstract.			
9A	32	Wulff "Molecular Imprinting in Cross-Linked Materials With the Aid of Molecular Templates - A Way Towards Artificial Antibodies", Angewandte Chemie, International Edition, 34: 1812-1832, 1995. Abstract.			
Signature		[Signature]		Considered	11/3/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.